Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Uncategorized

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

Breaking News

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

Breaking News

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

Breaking News

25 Feb 2026

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

Industry

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

Industry

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

Breaking News

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

Culture

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

Follow us on social

Latest News

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

WordPress Ads